New resources launched to help people navigate follicular lymphoma diagnosis
To mark Blood Cancer Awareness Month, FLF has launched new diagnosis resources and a patient-informed video to help people better understand follicular lymphoma and navigate the challenges of diagnosis.
A Field Full of Momentum: Mid-Year Progress and the Road Ahead in Follicular Lymphoma Research
The FLF’s Chief Medical Officer Dr Mitchell Smith, reviews major developments in follicular lymphoma research during the first half of 2026.
Introducing FL Voices: a new way to help shape the future of follicular lymphoma
FL Voices, is the Follicular Lymphoma Foundation’s flexible patient involvement network. Share your experiences, shape research, and make a difference.
Could some people with Follicular Lymphoma Be Cured? New evidence sparks careful optimism
New long-term research is raising one of the most important, and sensitive, questions in follicular lymphoma: could a subset of patients already be cured?
The FLF 2025 Global Patient Survey – what did we learn? Â
In October 2025, we conducted the FLF’s annual Global Patient Survey to better understand the challenges, concerns, and priorities of people living with follicular lymphoma. More than 1,000 people took part from over 50 countries worldwide – sharing their experiences across different stages of the disease and from healthcare systems around the world. These insights offer an important perspective on where support is working well and where further progress is needed.
Tazemetostat in Follicular Lymphoma: What Patients Need to Know After the Recent Market Withdrawal
On 9th March came the announcement that tazemetostat (Tazverik) is being voluntarily withdrawn worldwide. Ipsen, the company that markets tazemetostat, made this decision after new safety findings emerged from the ongoing SYMPHONY 1 clinical trial, which indicated a possible increased risk of secondary blood cancers when the drug was used in a specific combination regimen (lenalidomide and rituximab, also referred to as R2).
Epcoritamab Approved for Relapsed or Refractory Follicular Lymphoma on the NHS in England, Wales and Northern Ireland
NICE has approved epcoritamab (Tepkinly) on the NHS for adults in England, Wales and Northern Ireland with relapsed or refractory follicular lymphoma after two prior treatments. The decision introduces a new bispecific antibody therapy option for patients with limited treatment choices.
Celebrating the Women Researchers Driving Progress in Follicular Lymphoma ResearchÂ
This International Women’s Day the FLF and our global community are proud to celebrate and highlight the exceptional women whose scientific insight, dedication and innovation are driving progress in follicular lymphoma research.
Follicular Lymphoma Conclave Brings Global Experts Together to Accelerate Progress Towards a Cure
In February 2026, the Follicular Lymphoma Foundation and the Josep Carreras Leukaemia Research Institute convened a global Scientific Conclave in Barcelona to confront the barriers slowing progress toward cures for follicular lymphoma. Over three days, leading experts aligned around clear priorities and a coordinated strategy designed to turn insight into decisive action for patients.
Latest Research Breakthroughs at ASH 2025: How We’re Accelerating the Search for a Cure
Every December, over 30,000 haematology experts from around the world gather for the American Society of Haematology (ASH) conference, where groundbreaking research is shared and the future of lymphoma treatment takes shape. In December 2025, the FLF team was at ASH in Orlando, USA on a clear mission: to find out the latest breakthroughs, represent you and drive progress toward a cure for follicular lymphoma.